News

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates.

What Novanta’s latest guidance and Q2 results mean for the stock Novanta (NOVT) put fresh numbers on the table on 5 August 2026, pairing new third quarter and full year revenue guidance with second quarter results and the recently closed Riverpoint Medical acquisition. The company now guides third quarter 2026 GAAP revenue to US$300 million to US$304 million, with the range reflecting an expected contribution from Riverpoint Medical and an assumption of steady foreign exchange rates. For full...

Novanta (NasdaqGS:NOVT) has closed its acquisition of RiverPoint Medical, the largest deal in the company's history. The transaction expands Novanta's exposure to medical end markets and is expected to be immediately accretive to revenue growth and margins. Management is accelerating a manufacturing restructuring plan alongside the RiverPoint integration, with potential long-term effects on efficiency and profitability. For investors watching how medical technology companies scale up and...

Novanta Inc (NOVT) delivered robust Q2 2026 results with 9% organic growth, record cash flow, and raised full-year guidance following the Riverpoint Medical acquisition.

Novanta (NASDAQ:NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra sa

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm […]

Novanta (NOVT) delivered earnings and revenue surprises of +7.23% and +1.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) announced better-than-expected revenue in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates.

Universal Display (OLED) delivered earnings and revenue surprises of +1.92% and -3.93%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Novanta (NOVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Novanta (NOVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Since January 2026, Novanta has been in a holding pattern, posting a small return of 3.3% while floating around $142.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

Novanta was recently upgraded to a Zacks Rank #2 (Buy), reflecting increased analyst optimism tied to an upward revision in earnings estimates. This earnings-driven upgrade highlights how changing expectations about Novanta's profit outlook can influence investor attention and perceived business strength over time. Next, we'll examine how the upgraded earnings outlook and analyst ranking could reshape Novanta's existing investment narrative and risk profile. Invest in the nuclear...

Novanta (NOVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.12%. June E-mini S&P futures (ESM26 ) fell -0.36%, and June E-mini Nasdaq futures...

The deal will give Novanta entry into the minimally invasive surgery segment and is expected to bolster it position in the medical consumables space.

The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures (ESM26 ) are down -0.25%, and June E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...

Healthcare stocks were rising pre-bell Tuesday, with the State Street Health Care Select Sector SPDR

A number of stocks jumped in the morning session after the industrial sector recovered, carried by the broad market rebound and a read-through from AI-driven capital expenditure commitments.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Understanding Novanta after its recent share move Novanta (NOVT) has drawn investor attention after a recent share price move, prompting a closer look at how the company’s current fundamentals line up with its recent market performance. See our latest analysis for Novanta. Novanta’s recent share price move comes after a strong run, with a 30 day share price return of 24.6% and a year to date share price return of 43.36%. The 1 year total shareholder return is 28.68%, but the 3 year total...

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

A number of stocks jumped in the afternoon session after the Dow hit a fresh all-time high above 50,700 as yields cooled off. Industrials are the most direct play on physical economic activity.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Novanta (NASDAQ:NOVT) and its peers.

Novanta (NOVT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Novanta’s first quarter saw a strong positive market reaction, reflecting confidence in management’s execution and commercial momentum. The company credited broad-based demand and robust bookings, particularly in the Robotics & Automation and Advanced Surgery businesses, as central to its performance. CEO Matthijs Glastra highlighted that every segment achieved double-digit bookings growth, with new product revenue rising sharply. Management specifically pointed to ongoing strength in medical co